NCT03376659 - Durvalumab Plus CV301 With Maintenance Chemotherapy in Metastatic Colorectal or Pancreatic Adenocarcinoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 8, 2018

Primary Completion Date

August 30, 2021

Study Completion Date

August 1, 2023

Conditions

Metastatic Colorectal CancerColorectal AdenocarcinomaPancreatic AdenocarcinomaMetastatic Pancreatic Cancer

Interventions

DRUG

Durvalumab

750mg IV q2 weeks

BIOLOGICAL

CV301

"MVA-BN-CV301 (prime) - two priming doses of 1.6 x 109 infectious units/0.5 mL (Inf.U) given subcutaneously (s.c.)~FPV-CV301 (boost) - dosed at 1 × 109 Inf.U/0.5 mL given s.c."

DRUG

Capecitabine

1000mg orally twice a day, Monday - Friday Weekly

DRUG

Bevacizumab

5mg/kg IV q2weeks

Trial Locations (1)

20007

Lombardi Comprehensive Cancer Center, Washington D.C.